This trial is researching if a combination of ADT and darolutamide can help men with prostate cancer at high risk of biochemical recurrence (BCR) live longer without their cancer getting worse.
- Biochemically Recurrent Prostate Cancer
1 Primary · 10 Secondary · Reporting Duration: After randomization to after last treatment, approximately 46 months
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
750 Total Participants · 2 Treatment Groups
Primary Treatment: Darolutamide+ADT · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · Male Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there opportunities to participate in this medical experiment?
"It appears that this clinical trial has already filled its quota of patients, as the listing was last updated on March 21st 2023. Nonetheless, there are 1239 other trials currently recruiting participants at this time." - Anonymous Online Contributor
Has the Darolutamide+ADT drug combination been given clearance by the FDA?
"The safety of Darolutamide+ADT was rated a 3 due to the existence of evidence-backed efficacy and multiple rounds of research proving its safety." - Anonymous Online Contributor
In what areas of the country is this clinical trial accessible?
"This trial is currently being administered at 184 different medical facilities. These include Tucson, Duarte and Los Angeles, among other urban centres. Potential participants should consider choosing the clinic that's closest to them in order to limit their time spent commuting." - Anonymous Online Contributor